As demonstrated in the PACIFIC trial, the benefit of adjuvant PD-L1 blockade using durvalumab after chemoradiation in NSCLC is thought to be at least partially due to its ability to block inhibition of CD8+ cytotoxic T cells, which are presumably activated following chemoradiation. Here, CD274 is linked to non-small cell lung carcinoma.